top of page
About
Directors
Organizational Chart
Team
Laboratory
Research
Epidemiology
EARLY-PREG Cohort
Embryo-Mother Crosstalk
Prenatal Medicine
Clinical Trials
Publications
Research Articles
Pre-Prints
Patents
Book Chapters
Resources
Core Facility
Proteomics
Genomics
Chromatography
Bioinformatics
R&D Solutions
Communications
News
Biotech Blog
Press Clipping
Support us
PATENTS
Formulation, use and method for broad-spectrum prophylaxis and treatment of viral infections caused by SARS-CoV-2 and other emergent viruses
EGCG-Zn2+ molecular complexes exhibit a significantly higher affinity than the EGCG molecule alone or Zn2+ alone for binding to different SARS-CoV-2 molecular targets and show virtually complete antiviral suppressive activity (>99%) against this virus in experimental models of infection. EGCG-Zn2+ complexes have a lower toxicity than EGCG alone in transfected human cells. The combination of EGCG and Zn2+, significantly improved some key pharmacokinetic parameters of EGCG in humans. Thus, these complexes can be used as a new broad-spectrum method for chemoprophylaxis or treatment of viral diseases by using formulations containing a composition of EGCG and Zn2+ or EGCG-Zn2+ complexes in sufficient amount to reach a blood concentration with antiviral effect, minimizing safety issues in humans.
PubChem
|
PDF
|
bottom of page
%2020_02_30.png)